ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0682

Gout Management and Outcomes During the COVID-19 Pandemic in Late 2020-2021: A Cross-sectional Internet Survey

Jasvinder Singh1 and N Lawrence Edwards2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Florida College of Medicine, Gainesville, FL

Meeting: ACR Convergence 2021

Keywords: Access to care, COVID-19, gout

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: To assess gout management during the COVID-19 pandemic since September 2020.

Methods: We assessed urate-lowering therapy (ULT) use, healthcare utilization, gout-specific health-related quality of life (HRQOL; 0-100 range; higher scores = lower/pooper HRQOL), health literacy, illness perception, psychological distress using patient health questionnaire-4 (2 questions each for depression and anxiety; 0-6 each), and resilience using on Connor-Davidson Resilience Scale (CD-RISC2; range 0-8; higher=more resilient) scale in people with self-reported physician-diagnosed gout in a cross-sectional Internet survey.

Results: Among the 121 survey respondents with self-reported physician-diagnosed gout, 60% were prescribed urate-lowering therapy (ULT) and 33% were taking ULT daily since September 2020. The mean age of respondents was 62.8 years (standard deviation [SD], 12.6), 65% were male, and 82% were White. Regular daily use of gout medications was reported during the COVID-19 pandemic since September 2020 as follows: allopurinol, 31%; febuxostat, 4%; probenecid, 2%; colchicine, 7%; NSAIDs, 9%; glucocorticoids, 4%. Gout flares were common, i.e., 76% reported ≥1 gout flare. Overall, 29% of respondents reported more difficulty with managing their gout since September 2020.

Gout-specific HRQOL deficits were evident for all scales: (1) gout concern overall, 72.9 (SD, 25); (2) unmet gout treatment need, 54.2 (SD, 24.7); (3) gout concern during flare, 55.5 (SD, 24.5); (4) gout well-being during flare, 55.4 (SD, 23.6); and (5) gout medication side effects, 56.5 (SD, 25.5).

Psychological distress was moderate in 10% and severe in 14% (mild, 27%; none/normal, 50%). Resilience score was 6.5 (SD, 1.9). Health literacy was high with mean score of 18.5 (SD, 2.5; range 4-20).

Adjusted for age, and sex, compared to no depression or anxiety, depression with PHQ-2 score ≥3, and anxiety with PHQ-2 score of ≥3, were significantly associated with: (1) difficulty with getting healthcare for gout in clinic, emergency room or urgent care, and in-hospital; (2) difficulty getting gout flares treated, avoiding gout flares, and avoiding complications from gout; and (4) difficulty with daily activities, and performing work; and depression, but not anxiety with regular ULT use (Table 1).

Conclusion: Respondents with gout reported healthcare gaps, psychological distress, illness perception and HRQOL deficits since September 2020 during the COVID-19 pandemic. Anxiety and depression were associated with poorer ULT adherence and more difficulty managing gout. Interventions to address psychological comorbidity in gout are needed during the COVID-19 pandemic.

Table 1. Multivariable association of depression and anxiety with gout outcomes during COVID_19 pandemic in 2020_2021


Disclosures: J. Singh, Crealta/Horizon, 2, Medisys, 2, Fidia, 2, PK Med, 2, Two labs Inc, 2, Adept Field Solutions, 2, Clinical Care options, 2, Clearview healthcare partners, 2, Putnam associates, 2, Focus forward, 2, Navigant consulting, 2, Spherix, 2, MedIQ, 2, Jupiter Life Science, 2, UBM LLC, 2, Trio Health, 2, Medscape, 2, WebMD, 2, Practice Point communications, 2, the National Institutes of Health, 2, the American College of Rheumatology, 2, TPT Global Tech, 11, Vaxart pharmaceuticals, 11, Charlotte’s Web Holdings, Inc., 11, Amarin pharmaceuticals, 11, Viking pharmaceuticals, 11, Moderna pharmaceuticals, 11, speaker’s bureau of Simply Speaking, 6, member of the executive of Outcomes Measures in Rheumatology, 4; N. Edwards, None.

To cite this abstract in AMA style:

Singh J, Edwards N. Gout Management and Outcomes During the COVID-19 Pandemic in Late 2020-2021: A Cross-sectional Internet Survey [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/gout-management-and-outcomes-during-the-covid-19-pandemic-in-late-2020-2021-a-cross-sectional-internet-survey/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gout-management-and-outcomes-during-the-covid-19-pandemic-in-late-2020-2021-a-cross-sectional-internet-survey/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences